168 related articles for article (PubMed ID: 9405155)
1. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
Maga G; Amacker M; Ruel N; Hübscher U; Spadari S
J Mol Biol; 1997 Dec; 274(5):738-47. PubMed ID: 9405155
[TBL] [Abstract][Full Text] [Related]
2. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
5. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
7. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
8. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
9. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Stammers DK
J Mol Biol; 2004 Feb; 336(3):569-78. PubMed ID: 15095972
[TBL] [Abstract][Full Text] [Related]
11. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
[TBL] [Abstract][Full Text] [Related]
12. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
13. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
Kerr SG; Anderson KS
Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
[TBL] [Abstract][Full Text] [Related]
14. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
[TBL] [Abstract][Full Text] [Related]
16. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
[TBL] [Abstract][Full Text] [Related]
17. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
18. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
[TBL] [Abstract][Full Text] [Related]
20. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
